BMS-986163, a Negative Allosteric Modulator of GluN2B with Potential Utility in Major Depressive Disorder

There is a significant unmet medical need for more efficacious and rapidly acting antidepressants. Toward this end, negative allosteric modulators of the -methyl-d-aspartate receptor subtype GluN2B have demonstrated encouraging therapeutic potential. We report herein the discovery and preclinical profile of a water-soluble intravenous prodrug BMS-986163 () and its active parent molecule BMS-986169 (), which demonstrated high binding affinity for the GluN2B allosteric site ( = 4.0 nM) and selective inhibition of GluN2B receptor function (IC = 24 nM) in cells. The conversion of prodrug to parent was rapid in vitro and in vivo across preclinical species. After intravenous administration, compounds and have exhibited robust levels of ex vivo GluN2B target engagement in rodents and antidepressant-like activity in mice. No significant off-target activity was observed for , , or the major circulating metabolites and . The prodrug BMS-986163 () has demonstrated an acceptable safety and toxicology profile and was selected as a preclinical candidate for further evaluation in major depressive disorder.

Citing Articles

Demystifying the Antidepressant Mechanism of Action of Stinels, a Novel Class of Neuroplastogens: Positive Allosteric Modulators of the NMDA Receptor.

Donello J, McIntyre R, Pickel D, Stahl S Pharmaceuticals (Basel). 2025; 18(2).

PMID: 40005971 PMC: 11858332. DOI: 10.3390/ph18020157.

Therapeutic potential of N-methyl-D-aspartate receptor modulators in psychiatry.

Hanson J, Yuan H, Perszyk R, Banke T, Xing H, Tsai M Neuropsychopharmacology. 2023; 49(1):51-66.

PMID: 37369776 PMC: 10700609. DOI: 10.1038/s41386-023-01614-3.

Structure, Function, and Pharmacology of Glutamate Receptor Ion Channels.

Hansen K, Wollmuth L, Bowie D, Furukawa H, Menniti F, Sobolevsky A Pharmacol Rev. 2021; 73(4):298-487.

PMID: 34753794 PMC: 8626789. DOI: 10.1124/pharmrev.120.000131.

A Glutamate -Methyl-d-Aspartate (NMDA) Receptor Subunit 2B-Selective Inhibitor of NMDA Receptor Function with Enhanced Potency at Acidic pH and Oral Bioavailability for Clinical Use.

Myers S, Ruppa K, Wilson L, Tahirovic Y, Lyuboslavsky P, Menaldino D J Pharmacol Exp Ther. 2021; 379(1):41-52.

PMID: 34493631 PMC: 8626636. DOI: 10.1124/jpet.120.000370.

Synthesis and Preliminary Evaluations of a Triazole-Cored Antagonist as a PET Imaging Probe ([F]N2B-0518) for GluN2B Subunit in the Brain.

Fu H, Tang W, Chen Z, Belov V, Zhang G, Shao T ACS Chem Neurosci. 2019; 10(5):2263-2275.

PMID: 30698943 PMC: 6727982. DOI: 10.1021/acschemneuro.8b00591.

References

Preskorn S, Baker B, Kolluri S, Menniti F, Krams M, Landen J . An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. J Clin Psychopharmacol. 2008; 28(6):631-7. DOI: 10.1097/JCP.0b013e31818a6cea. View

Racagni G, Popoli M . Cellular and molecular mechanisms in the long-term action of antidepressants. Dialogues Clin Neurosci. 2009; 10(4):385-400. PMC: 3181899. View

Miller O, Yang L, Wang C, Hargroder E, Zhang Y, Delpire E . GluN2B-containing NMDA receptors regulate depression-like behavior and are critical for the rapid antidepressant actions of ketamine. Elife. 2014; 3:e03581. PMC: 4270067. DOI: 10.7554/eLife.03581. View

Lener M, Kadriu B, Zarate Jr C . Ketamine and Beyond: Investigations into the Potential of Glutamatergic Agents to Treat Depression. Drugs. 2017; 77(4):381-401. PMC: 5342919. DOI: 10.1007/s40265-017-0702-8. View

Rush A, Trivedi M, Wisniewski S, Nierenberg A, Stewart J, Warden D . Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006; 163(11):1905-17. DOI: 10.1176/ajp.2006.163.11.1905. View

Graef J, Newberry K, Newton A, Pieschl R, Shields E, Luan F . Effect of acute NR2B antagonist treatment on long-term potentiation in the rat hippocampus. Brain Res. 2015; 1609:31-9. DOI: 10.1016/j.brainres.2015.03.019. View

Abdallah C, Adams T, Kelmendi B, Esterlis I, Sanacora G, Krystal J . KETAMINE'S MECHANISM OF ACTION: A PATH TO RAPID-ACTING ANTIDEPRESSANTS. Depress Anxiety. 2016; 33(8):689-97. PMC: 4961540. DOI: 10.1002/da.22501. View

Tyler M, Yourish H, Ionescu D, Haggarty S . Classics in Chemical Neuroscience: Ketamine. ACS Chem Neurosci. 2017; 8(6):1122-1134. DOI: 10.1021/acschemneuro.7b00074. View

Preston T, Shelton R . Treatment resistant depression: strategies for primary care. Curr Psychiatry Rep. 2013; 15(7):370. DOI: 10.1007/s11920-013-0370-7. View

10.

Ibrahim L, Diaz Granados N, Jolkovsky L, Brutsche N, Luckenbaugh D, Herring W . A Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder. J Clin Psychopharmacol. 2012; 32(4):551-7. PMC: 3438886. DOI: 10.1097/JCP.0b013e31825d70d6. View

11.

Mony L, Kew J, Gunthorpe M, Paoletti P . Allosteric modulators of NR2B-containing NMDA receptors: molecular mechanisms and therapeutic potential. Br J Pharmacol. 2009; 157(8):1301-17. PMC: 2765303. DOI: 10.1111/j.1476-5381.2009.00304.x. View

12.

Burger P, Yuan H, Karakas E, Geballe M, Furukawa H, Liotta D . Mapping the binding of GluN2B-selective N-methyl-D-aspartate receptor negative allosteric modulators. Mol Pharmacol. 2012; 82(2):344-59. PMC: 3400845. DOI: 10.1124/mol.112.078568. View

13.

Machado-Vieira R, Henter I, Zarate Jr C . New targets for rapid antidepressant action. Prog Neurobiol. 2016; 152:21-37. PMC: 4919246. DOI: 10.1016/j.pneurobio.2015.12.001. View

14.

Zanos P, Moaddel R, Morris P, Georgiou P, Fischell J, Elmer G . NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature. 2016; 533(7604):481-6. PMC: 4922311. DOI: 10.1038/nature17998. View

15.

Bristow L, Gulia J, Weed M, Srikumar B, Li Y, Graef J . Preclinical Characterization of ()-3-((3,4)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one (BMS-986169), a Novel, Intravenous, Glutamate -Methyl-d-Aspartate 2B Receptor Negative Allosteric Modulator with Potential in.... J Pharmacol Exp Ther. 2017; 363(3):377-393. DOI: 10.1124/jpet.117.242784. View

16.

Feyissa A, Chandran A, Stockmeier C, Karolewicz B . Reduced levels of NR2A and NR2B subunits of NMDA receptor and PSD-95 in the prefrontal cortex in major depression. Prog Neuropsychopharmacol Biol Psychiatry. 2008; 33(1):70-5. PMC: 2655629. DOI: 10.1016/j.pnpbp.2008.10.005. View

17.

Ferrari A, Charlson F, Norman R, Patten S, Freedman G, Murray C . Burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010. PLoS Med. 2013; 10(11):e1001547. PMC: 3818162. DOI: 10.1371/journal.pmed.1001547. View

18.

Paoletti P, Bellone C, Zhou Q . NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease. Nat Rev Neurosci. 2013; 14(6):383-400. DOI: 10.1038/nrn3504. View

19.

Newport D, Carpenter L, McDonald W, Potash J, Tohen M, Nemeroff C . Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression. Am J Psychiatry. 2015; 172(10):950-66. DOI: 10.1176/appi.ajp.2015.15040465. View

20.

Zhang M, Harris K, Ho R . Is off-label repeat prescription of ketamine as a rapid antidepressant safe? Controversies, ethical concerns, and legal implications. BMC Med Ethics. 2016; 17:4. PMC: 4714497. DOI: 10.1186/s12910-016-0087-3. View